Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Research & Development (2016 - 2025)

Regenxbio has reported Research & Development over the past 12 years, most recently at $59.6 million for Q4 2025.

  • Quarterly results put Research & Development at $59.6 million for Q4 2025, up 18.32% from a year ago — trailing twelve months through Dec 2025 was $228.3 million (up 9.48% YoY), and the annual figure for FY2025 was $228.3 million, up 9.48%.
  • Research & Development for Q4 2025 was $59.6 million at Regenxbio, up from $56.1 million in the prior quarter.
  • Over the last five years, Research & Development for RGNX hit a ceiling of $63.3 million in Q3 2022 and a floor of $39.7 million in Q1 2021.
  • Median Research & Development over the past 5 years was $55.7 million (2022), compared with a mean of $54.6 million.
  • Biggest five-year swings in Research & Development: surged 40.04% in 2022 and later fell 18.4% in 2024.
  • Regenxbio's Research & Development stood at $48.0 million in 2021, then soared by 30.28% to $62.5 million in 2022, then fell by 10.92% to $55.7 million in 2023, then decreased by 9.52% to $50.4 million in 2024, then rose by 18.32% to $59.6 million in 2025.
  • The last three reported values for Research & Development were $59.6 million (Q4 2025), $56.1 million (Q3 2025), and $59.5 million (Q2 2025) per Business Quant data.